The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Clinical trial club | Navtemadlin vs best available therapy in relapsed or refractory myelofibrosis
Featured:
Laura Michaelis
Haifa Kathrin Al-Ali
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 3
Which one of the following statements is true regarding the mechanism of action of MDM2?
A
B
C
D
On July 19, 2022, Scientific Education Support held its first clinical trial club, entitled “BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/refractory MF.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, entitled “Novel agents for the treatment of advanced myelofibrosis.”
The live webinar aimed to discuss the phase II and phase III navtemadlin clinical trials (NCT03662126), investigating navtemadlin, a murine double minute 2 (MDM2) inhibitor, in patients with myelofibrosis (MF) who relapse on, or are refractory to, Janus kinase (JAK) inhibitors. The event was chaired by Laura Michaelis, Medical College of Wisconsin, Milwaukee, US, and presented by the trial investigator Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE.
During the webinar, Haifa Kathrin Al-Ali talked about MDM2 inhibition in MF, and presented safety and efficacy data from the phase II trial. Subsequently, the two speakers discussed what these findings, and the ongoing randomized controlled phase III BOREAS trial, mean for clinical practice, which was followed by a live Q&A session.
Clinical trial club: Navtemadlin vs best available therapy in relapsed or refractory myelofibrosis
What do the navtemadlin trials mean for clinical practice?
Overview of the navtemadlin trials (NCT03662126)
MDM2 inhibition in MF
Key phase II efficacy and safety findings
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
